

Nimodipine

Nimodipine dosing may be weight based; ensure accuracy of documented weight before administration

CAUTION: High Administration Risk Rating

Form	10mg/50mL Infusion bottle									
Reconstitution	Already in solution									
Compatibility & Stability	Sodium Chloride 0.9% Glucose 5% <ul style="list-style-type: none"> • Incompatible with PVC Use polyethylene or polypropylene syringes 	Protect Infusion from light								
Administration	<p>IV Continuous Infusion Administer as a continuous IV infusion via a central catheter using an infusion pump. Connect to a three-way stopcock using the infusion line provided. The three-way stopcock should be used to connect the Nimodipine polyethylene tube with the co-infusion line and the central catheter. (The stopcock must allow for concomitant flow of the Nimodipine solution and a co-infusion solution.)</p> <table border="1"> <thead> <tr> <th colspan="2">Rate to run co-infusion fluid at</th> </tr> <tr> <th>Nimodipine Rate</th> <th>Rate of administration of co-infusion fluid</th> </tr> </thead> <tbody> <tr> <td>1mg/hour (5mL/hour)</td> <td>20mL/hour</td> </tr> <tr> <td>2mg/hour (10mL/hour)</td> <td>40mL/hour</td> </tr> </tbody> </table> <p>i.e. For every 5mL per hour of nimodipine infused 20mL per hour of a compatible fluid must be infused simultaneously to prevent formation of crystals.</p>		Rate to run co-infusion fluid at		Nimodipine Rate	Rate of administration of co-infusion fluid	1mg/hour (5mL/hour)	20mL/hour	2mg/hour (10mL/hour)	40mL/hour
Rate to run co-infusion fluid at										
Nimodipine Rate	Rate of administration of co-infusion fluid									
1mg/hour (5mL/hour)	20mL/hour									
2mg/hour (10mL/hour)	40mL/hour									
Extravasation	Extravasation is likely to cause tissue damage due to the presence of alcohol as an excipient and high osmolarity.									
Monitoring	Monitor BP and heart rate. Monitor renal function (including fluid balance) in patients with renal disease and/or receiving nephrotoxic drugs. A transient rise in liver enzymes may occur during intravenous administration; this usually reverts to normal on completion of treatment.									
Additional Information	<ul style="list-style-type: none"> • IV infusions should not be used concurrently with Nimodipine oral tablets. • Use only the infusion container and the infusion line provided by the manufacturer. • Each 50 ml vial also contains 10 g of ethanol (0.2 g/ml) • Prepare a fresh infusion if required once 10 hours has elapsed. 									

Information provided relates to Nimotop manufactured by Bayer

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from pharmacy on 22142 or 22546.